Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription


2 Ann Surg Oncol
1 Biochem Biophys Res Commun
1 BMC Cancer
1 BMC Ophthalmol
2 Br J Cancer
1 Br J Dermatol
2 J Am Acad Dermatol
1 J Clin Invest
1 J Immunol
2 J Immunother

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. TAYLOR NA, Brodland DG
    CT and PET-CT Surveillance in Stages 3A to 3D Melanoma Results in More False-Positive than True-Positive Findings and Should Not be Routinely Recommended.
    Ann Surg Oncol. 2021 Mar 18. pii: 10.1245/s10434-021-09820.

  2. HARRELL SHRECKENGOST CS, Tariq M, Farley CR, Zhang C, et al
    The Impact of Obesity on Surgically Treated Locoregional Melanoma.
    Ann Surg Oncol. 2021 Mar 14. pii: 10.1245/s10434-021-09773.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  3. CHOI SH, Shin I, Kim N, Nam Y, et al
    The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
    Biochem Biophys Res Commun. 2020;532:315-320.
    PubMed         Abstract available

    BMC Cancer

  4. KINIWA Y, Nakamura K, Mikoshiba A, Ashida A, et al
    Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    BMC Cancer. 2021;21:287.
    PubMed         Abstract available

    BMC Ophthalmol

  5. FANG R, Wang H, Li Y, Liu YM, et al
    Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy.
    BMC Ophthalmol. 2021;21:137.
    PubMed         Abstract available

    Br J Cancer

  6. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed         Abstract available

  7. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.

    Br J Dermatol

  8. ROBERTS MR, Asgari MM, Toland AE
    Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet?
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17917.
    PubMed         Abstract available

    J Am Acad Dermatol

  9. VOGEL RI, Jewett PI, Ahmed RL, Lazovich D, et al
    Comparison of sun exposure and protection behaviors between urban and rural residents without a history of melanoma in the Midwestern United States.
    J Am Acad Dermatol. 2021 Feb 3. pii: S0190-9622(21)00304.

  10. THOMPSON LL, Chang MS, Polyakov NJ, Blum AE, et al
    Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors.
    J Am Acad Dermatol. 2021 Mar 12. pii: S0190-9622(21)00563.

    J Clin Invest

  11. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    PubMed         Abstract available

    J Immunol

  12. SINGH S, Xiao Z, Bavisi K, Roszik J, et al
    IL-1alpha Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
    J Immunol. 2021 Mar 15. pii: jimmunol.2000523. doi: 10.4049/jimmunol.2000523.
    PubMed         Abstract available

    J Immunother

  13. COWEY CL, Scherrer E, Boyd M, Aguilar KM, et al
    Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    J Immunother. 2021 Mar 17. pii: 00002371-900000000-99347.
    PubMed         Abstract available

  14. STURMER SH, Lechner A, Berking C
    Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors.
    J Immunother. 2021 Mar 17. pii: 00002371-900000000-99346.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.